Transition Therapeutics, Inc.
(NASDAQ: TTHI) is a biopharmaceutical company developing novel therapeutics for
disease indications with large markets. The company’s leading drug candidate,
ELND005, is designed to treat the agitation and aggression associated with
Alzheimer’s disease and Down syndrome. Additionally, Transition is developing
TT401, a metabolic drug candidate formulated to treat Type 2 diabetes and its
accompanying obesity. Through the continued development and clinical testing of
these two products, the company is addressing medical markets that are
currently underserved.
According to the Alzheimer’s
Association, an estimated 5.3 million Americans of all ages currently suffer
from Alzheimer’s disease. Among those individuals, up to 60 percent will
develop behavioral symptoms, such as agitation or aggression, over the course
of their lives. Transition is making progress toward improving the comfort of
those affected by these symptoms through the continued development of ELND005.
In a completed phase 2 study, the drug candidate appeared to decrease the
emergence and severity of these neuropsychiatric symptoms by reducing
myo-inositol levels in the brain.
In March, Transition took a major
step toward the commercialization of its leading drug candidate through the
completion of absorption-metabolism-excretion (AME) and renal clearance
studies. These trials are required by the United States Food and Drug
Administration for the approval of nearly all drugs in development. In both
cases, ELND005 demonstrated good safety and tolerability, clearing the path for
more advanced clinical trials moving forward.
The company’s product pipeline
was expanded in May when Transition announced that its wholly owned subsidiary
had acquired exclusive worldwide licensing rights to TT701, a selective
androgen receptor modulator that’s been shown to significantly increase lean
body mass and muscle strength in male subjects.
“The safety and efficacy profile
of TT701 creates a number of development opportunities,” stated Dr. Tony Cruz,
chairman and chief executive officer of Transition. “[The company] will
initiate development and manufacturing activities to enable the start of a
phase 2 study in the coming months.”
Transition is expected to
continue making progress toward the commercialization of its robust product
pipeline moving forward. With phase 2 clinical trials for three drug candidates
in four unique indications ongoing, completed or upcoming, the company appears
to be closing in on a significant opportunity to realize sustainable returns in
the years to come.
For more information, visit
www.transitiontherapeutics.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
